Drawing for TAGWORKS

USPTO serial 90873410

TAGWORKS

Reviewed by CopyMark Law Group

Reg. 7265620Status 700Registered
Filing date
Status date
Registration date
Jan 9, 2024
Examiner
ALTREE, NICHOLAS
Law office
PUBLICATION AND ISSUE SECTION

What this means

Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.

Status 700: Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six.

Need help with TAGWORKS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Michael Fedrick

Michael Fedrick LOZA & LOZA, LLP305 N. SECOND AVE. #127UPLAND, CA 91786-6064United States

Goods and services

ClassDescriptionStatusFirst use
001chemical preparations for use in industry and science; chemical preparations and kits comprised of chemical preparations, for use in modifying or isolating biological materials; chemical preparations for solid phase chemistry or separation technology, such as coated polymers, in bead or resin form, for use in manufacturingACTIVE—
005pharmaceutical and veterinary preparations, namely, T-cell engaging biologics or drug conjugates based on biologics for therapy, biologics for immunoimaging, immunotherapy; pharmaceutical and veterinary preparations, namely, antibodies, antibody fragments, peptides or small molecules for immunotherapy treatment; pharmaceutical and veterinary nanoparticles, namely, polymers, liposomes, or antibodies modified with a chemical tag or a radiolabeled chemical tag, for nuclear imaging or therapy; pharmaceutical preparations for treatment or prevention of cancer, autoimmune or infectious disease; pharmaceutical and chemical preparations for medical purposes, namely, chemical probes or chemical tags conjugated to biologics for the treatment of cancer, autoimmune disease, or infectious disease; sanitary preparations for medical purposes; biopharmaceutical preparations for use in human and veterinary medicine for treatment of cancer, autoimmune diseases and infectious diseases; diagnostic preparations for medical purposes; chemical reagents for medical and veterinary purposes; chemicals and biological substances for medical use, namely, diagnostic reagents; pharmaceutical and veterinary preparations, namely, immune cell engaging biologics, preparations for imaging, prodrugs, or drug conjugates based on biologics for therapy, biologics, peptides or small molecules for radiotherapy, immunotherapy or chemotherapy; pharmaceutical and veterinary nanoparticles, namely, polymers, liposomes, biologics, peptides, or small molecules modified with a chemical tag or linker or a radiolabelled chemical tag, for nuclear imaging or therapy; pharmaceutical and chemical preparations for medical purposes, namely, chemical probes or chemical tags or linkers conjugated to biologics for the treatment of cancer, autoimmune disease, or infectious diseaseACTIVE—
042scientific and technological research in the field of immunoimaging and immunotherapy to provide T-cell engaging biologics or preparations for imaging or drug conjugates based on antibodies, antibody fragments, peptides, nanoparticle polymers or nanoparticle liposomes, or radiolabeled antibodies for nuclear imaging or therapy, or to provide preparations for medical diagnostics; scientific and technological research, in the field of imaging or immunotherapy to provide immune-cell engaging biologics or preparations for imaging or drug conjugates based on biologics for therapy, namely, antibodies, antibody fragments, peptides, or small molecules, nanoparticle polymers or nanoparticle liposomes, or radiolabelled antibodies, biologics, peptides and small molecules for nuclear imaging or therapy, or to provide preparations for medical diagnosticsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jan 9, 2024NRCCNOTICE OF REGISTRATION CONFIRMATION EMAILED—
Jan 9, 2024R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Dec 4, 2023DP1B1(B) BASIS DELETED; PROCEED TO REGISTRATION—
Sep 19, 2023NOACCORRECTED NOA E-MAILED—
Sep 18, 2023ICNANOTICE OF ALLOWANCE CORRECTION ENTERED—
Aug 23, 2023IUCNNOTICE OF ALLOWANCE CANCELLED—
Aug 23, 2023EPPATEAS POST PUBLICATION AMENDMENT RECEIVED—
Aug 10, 2023AITUCASE ASSIGNED TO INTENT TO USE PARALEGAL—
Jun 20, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jun 16, 2023INOAAMENDMENT AFTER NOA NOT ENTERED—
Jun 16, 2023EPPATEAS POST PUBLICATION AMENDMENT RECEIVED—
Jun 16, 2023EX1GSOU EXTENSION 1 GRANTED—
Jun 16, 2023EXT1SOU EXTENSION 1 FILED—
Jun 16, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 3, 2023NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Nov 8, 2022NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Nov 8, 2022PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Oct 19, 2022NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 6, 2022CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 6, 2022XAECEXAMINER'S AMENDMENT ENTERED—
Oct 6, 2022GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Oct 6, 2022GNEAEXAMINERS AMENDMENT E-MAILED—
Oct 6, 2022CNEAEXAMINERS AMENDMENT -WRITTEN—
May 11, 2022GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 11, 2022GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 11, 2022CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
May 7, 2022DOCKASSIGNED TO EXAMINER—
Oct 1, 2021NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Aug 12, 2021NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance